Search results for "Renal Cell Carcinoma"

showing 10 items of 164 documents

VHL gēna mutācijas gaišo šūnu nieru karcinomas gadījumā

2019

Nieru šūnu karcinoma ir sestais biežāk diagnosticētais audzējs no visām onkoloģiskajām diagnozēm pasaulē. Gaišo šūnu nieru karcinoma ir 65-70% no visiem saslimšanas gadījumiem ar nieru audzējiem. Izmaiņas von Hippel-Lindau (VHL) gēnā, kurš ir visbiežāk mutētais gēns gaišo šūnu nieru karcinomas gadījumā, tiek salīdzinātas starp in vitro audzētām cilvēku nieru proksimālo kanāliņu epitēlija šūnām un gaišo šūnu nieru karcinomas šūnu līnijām un primārajām šunām, kuras iegūtas no gaišo šūnu nieru karcinomas pacientu audiem un blakus esošiem veselajiem audiem. Darba rezultātā tika konstatēts viena nukleotīda polimorfisms pacientu gaišo šūnu nieru karcinomas audos un veselajos audos no VHL gēna izo…

gaišo šūnu nieru karcinomaFarmācijaclear cell renal cell carcinomavon Hippel-Lindau
researchProduct

Prediction of significant renal function decline after open, laparoscopic, and robotic partial nephrectomy: External validation of the Martini’s nomo…

2022

Objectives: Martini et al. developed a nomogram to predict significant (>25%) renal function loss after robot-assisted partial nephrectomy and identified four risk categories. We aimed to externally validate Martini’s nomogram on a large, national, multi-institutional data set including open, laparoscopic, and robot-assisted partial nephrectomy. Methods: Data of 2584 patients treated with partial nephrectomy for renal masses at 26 urological Italian centers (RECORD2 project) were collected. Renal function was assessed at baseline, on third postoperative day, and then at 6, 12, 24, and 48 months postoperatively. Multivariable models accounting for variables included in the Martini’s nomog…

laparoscopy; nephron-sparing surgery; renal cell carcinoma; renal function; robotics; Humans; Kidney; Nephrectomy; Nomograms; Kidney Neoplasms; Laparoscopy; Robotic Surgical Procedures; Roboticsroboticsrenal cell carcinomaUrologyrenal functionlaparoscopynephron-sparing surgeryKidneyNephrectomyKidney NeoplasmsNomogramsRobotic Surgical ProceduresHumansLaparoscopyrobotics.Laparoscopy; nephron-sparing surgery; renal cell carcinoma; renal function; robotics.International Journal of Urology
researchProduct

Is the Complement Protein C1q a Pro- or Anti-tumorigenic Factor? Bioinformatics Analysis Involving Human Carcinomas

2019

C1q is the first subcomponent of the classical pathway of the complement system and belongs to the C1q/Tumor Necrosis Factor superfamily. C1q can perform a diverse range of immune and non-immune functions in a complement-dependent as well as -independent manner. Being a pattern recognition molecule of the innate immunity, C1q can recognize a number of self, non-self and altered-self ligands and bring about effector mechanisms designed to clear pathogens via opsonisation and inflammatory response. C1q is locally synthesized by macrophages and dendritic cells, and thus, can get involved in a range of biological processes, such as angiogenesis and tissue remodeling, immune modulation, and immu…

lcsh:Immunologic diseases. Allergy0301 basic medicinetumorLung NeoplasmsMicroenvironmentPrognosiImmunologyComplementBreast Neoplasmschemical and pharmacologic phenomenaKaplan-Meier EstimateBiology03 medical and health sciencesClassical complement pathway0302 clinical medicineImmune systemimmune system diseasesmedicineHumansImmunology and Allergycomplementclassical pathwayskin and connective tissue diseasesC1qOriginal ResearchTumorInnate immune systemEffectorComplement C1qComputational BiologyCancerPrognosismedicine.diseasemicroenvironmentKidney NeoplasmsComplement systemClear cell renal cell carcinomaC1q; Classical pathway; Complement; Microenvironment; Prognosis; Tumor030104 developmental biologyClassical pathwayCancer researchAdenocarcinomaprognosislcsh:RC581-607030215 immunologyFrontiers in Immunology
researchProduct

CT and MR imaging of cystic renal lesions

2020

AbstractCystic renal lesions are a common incidental finding on routinely imaging examinations. Although a benign simple cyst is usually easy to recognize, the same is not true for complex and multifocal cystic renal lesions, whose differential diagnosis includes both neoplastic and non-neoplastic conditions. In this review, we will show a series of cases in order to provide tips to identify benign cysts and differentiate them from malignant ones.

lcsh:Medical physics. Medical radiology. Nuclear medicinemedicine.medical_specialtymedicine.diagnostic_testbusiness.industrySimple cystlcsh:R895-920UltrasoundInterventional radiologyMRMr imagingBenign cystsCystic renal lesionCystic renal cell carcinomamedicineRadiology Nuclear Medicine and imagingRadiologyDifferential diagnosisbusinessBosniakNeuroradiologyEducational ReviewCTInsights into Imaging
researchProduct

Metástasis óseas secundarias a carcinoma renal diagnosticadas mediante gammagrafía ósea

2001

We reported the case of a 35-y-old man with renal cell carcinoma and cold lesions detected by bone scintigraphy, related to metastatic involvement. Conventional X-Ray did not show any pathological findings, being confirmed by axial computed tomography (CT) the scintigraphic bone lesions. We have accomplished a discussion of the role of bone scintigraphy and complementary techniques (radiography, alkaline phosphatase levels) in the diagnosis of bone metastases in renal cell carcinoma.

medicine.diagnostic_testbusiness.industryUrologyRadiographyComputed tomographymedicine.diseaseBone scintigraphyRenal cell carcinomaBone lesionCarcinomaMedicineAlkaline phosphatasebusinessNuclear medicinePathologicalActas Urológicas Españolas
researchProduct

Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy

2003

Renal cell carcinoma (RCC) represents the most common malignant tumor in the kidney and is resistant to conventional therapies. The diagnosis of RCC is often delayed leading to progression and metastatic spread of the disease. Thus, validated markers for the early detection of the disease as well as selection of patients undergoing specific therapy is urgently needed. Using treatment with the monoclonal antibody (mAb) G250 as a model, proteome-based strategies were implemented for the identification of markers which may allow the discrimination between responders and nonresponders prior to application of G250-mediated immunotherapy. Flow cytometry revealed G250 surface expression in approxi…

medicine.drug_classmedicine.medical_treatmentMonoclonal antibodyBiochemistryMass SpectrometryFlow cytometrySequence Analysis ProteinRenal cell carcinomaCell Line TumorBiomarkers TumormedicineCarcinomaHumansElectrophoresis Gel Two-DimensionalCarcinoma Renal CellMolecular Biologybiologymedicine.diagnostic_testAntibodies MonoclonalProteinsImmunotherapyFlow Cytometrymedicine.diseaseKidney NeoplasmsImmunologyProteomebiology.proteinCancer researchImmunohistochemistryImmunotherapyAntibodyPROTEOMICS
researchProduct

Sunitinib related osteonecrosis of the jaw (SURONJ): a rare occurrence?

2015

Sir, Sunitinib is a drug approved in 2006 by the FDA for the treatment of renal cell carcinoma (RCC) and resistant gastrointestinal stromal tumor (GIST). The capillary endothelium is the first target of sunitinib: it blocks several pathways central to proliferation, migration, differentiation, neoangiogenesis, and invasion of cancer cells, including vascular endothelial growth factor receptors (VEGFRs), plateletderived growth factor receptors (PDGFR-α and PGRF-β), the stem cell factor receptor (c-Kit) and the Fms-like tyrosine kinase 3 (FLT3), and glial cell–derived neurotrophic factor receptor (RET), colony-stimulating factor type 1 (CSF-1R) [1, 2, 9]. In literature, several adverse effect…

medicine.medical_specialtyChemotherapybusiness.industrySunitinibmedicine.medical_treatmentOsteomyelitis030206 dentistrymedicine.diseaseNephrectomySurgerySunitinib osteonecrosis03 medical and health sciences0302 clinical medicineDental extractionRenal cell carcinoma030220 oncology & carcinogenesismedicineMucositisSurgerybusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Prognostic Parameters in Renal Cell Carcinoma - a New Approach(1)

1989

The prognostic potential of the parameters TNM staging, Robson staging, grading, cell type, growth pattern, and patient age was investigated for 431 patients with operated renal cell carcinoma (RCC). In the individual analyses, staging and grading attained the best results, whereby Robson staging proved to be superior to TNM staging by comparison. Morphological parameters had a more modest effect on the prognosis, but this should not be underestimated. A scale of points based on a comparative biometric evaluation of the various parameters was devised. From this scale, three significantly distinct prognostic groups evolved with a correct prognosis of over 80% on the average for an individual…

medicine.medical_specialtyEpitheliomabusiness.industryUrologymedicine.diseaseSurgeryRenal cell carcinomaPatient ageCarcinomaMedicineTNM StagingRadiologybusinessGrading (tumors)European Urology
researchProduct

Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large m…

2020

Abstract Background Aim of this study was to evaluate and compare perioperative outcomes of transperitoneal (TP) and retroperitoneal (TR) approaches in a multi-institutional cohort of minimally invasive partial nephrectomy (MI-PN). Material and methods All consecutive patients undergone MI-PN for clinical T1 renal tumors at 26 Italian centers (RECORd2 project) between 01/2013 and 12/2016 were evaluated, collecting the pre-, intra-, and postoperative data. The patients were then stratified according to the surgical approach, TP or RP. A 1:1 propensity score (PS) matching was performed to obtain homogeneous cohorts, considering the age, gender, baseline eGFR, surgical indication, clinical dia…

medicine.medical_specialtyIntraoperative ComplicationUrologymedicine.medical_treatmentOperative TimeSurgical approach030232 urology & nephrologyMinimally invasive partial nephrectomy Renal cell carcinoma Retroperitoneal Surgical approach Transperitoneal.lcsh:RC870-923lcsh:RC254-282NephrectomyArticle03 medical and health sciences0302 clinical medicineRenal cell carcinomamedicineMinimally invasive partial nephrectomy; Renal cell carcinoma; Retroperitoneal; Surgical approach; TransperitonealHumansRetroperitoneal SpaceRetrospective StudiesMinimally invasive partial nephrectomybusiness.industryRenal cell carcinoma; Minimally invasive partial nephrectomy; Transperitoneal; Retroperitoneal; Surgical approachTransperitonealPerioperativeRetroperitoneallcsh:Diseases of the genitourinary system. Urologylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseNephrectomyKidney NeoplasmsRenal cell carcinomaSurgerySettore MED/24Treatment Outcome030220 oncology & carcinogenesisPropensity score matchingCohortSurgeryLaparoscopyPositive Surgical MarginMinimally invasive partial nephrectomy; Renal cell carcinoma; Retroperitoneal; Surgical approach; Transperitoneal; Follow-Up Studies; Humans; Nephrectomy; Operative Time; Retroperitoneal Space; Retrospective Studies; Treatment Outcome; Kidney Neoplasms; LaparoscopybusinessAbdominal surgeryFollow-Up StudiesSurgical endoscopy
researchProduct

Ductal lavage: a way of carefully tracing the breast-secreting duct

2006

Background: Breast cancer is the most commonly diagnosed neoplasia in women after nonmelanoma skin tumors. Unfortunately, present-day diagnostic methods are unable to identify the presence of a cancer until it has been developing for several years. Currently, ductal lavage seems to represent a new method of reaching an early diagnosis of breast cancer. Materials & methods: This study analyzed 30 patients with ages ranging from 40 to 55 years; and in 26 of these patients, we were able to obtain a sufficient quantity of material for cytological and biomolecular analysis. Results & conclusion: We propose an easy, reproducible method that makes it possible to obtain a detailed map of the nipple…

medicine.medical_specialtyKidneyDuctal lavagebiologySettore MED/06 - Oncologia Medicabusiness.industrymedicine.medical_treatmentUrologyGeneral Medicinemedicine.diseaseSurgeryductal lavagemedicine.anatomical_structureRenal cell carcinomamedicineCarcinomaAdjuvant therapybiology.proteinPharmacology (medical)HemodialysisAntibodybusinessDuct (anatomy)Therapy
researchProduct